Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets. The company’s technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for process development, from research to manufacturing. The company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and Codex Biocatalyst Kits and Panels. It markets and sells enzymes, development services and Codex Biocatalyst Kits and Panels screening tools that enable novel manufacturing processes for APIs and their precursor pharmaceutical intermediates. The company also markets and sells pharmaceutical intermediates that are manufactured using custom enzymes. Its customers include pharmaceutical companies. Products and Services Codex Biocatalyst Panels and Kits The company sells Codex Biocatalyst Panels and Kits to customers who are engaged in both drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. Codex Biocatalyst Panels are tools that provide genetically diverse variants of its proprietary enzymes, which allow its customers to determine whether an enzyme produces a desired activity that is applicable to a particular process. Codex Biocatalyst Kits provide subsets of the Panel enzymes in individual vials for the same purpose. For compounds that are in development, Codex Biocatalyst Panels and Kits allow innovators to screen and identify possible enzymatic manufacturing processes for majority of their drug candidates in-house, without the risks of disclosing the composition of their proprietary molecules before they have received patent protection; and generate data that the company could use to optimize enzymes for a particular reaction, if necessary, reducing the time required to generate a manufacturing process capable of supporting clinical trials with inexpensively produced, pure drugs. Enzyme Screening Services The company’s screening services allow innovators to screen and identify possible enzymatic manufacturing processes through access to its enzyme libraries; and generate data that the company could use to optimize enzymes for a particular reaction, if necessary, reducing the time required to generate a manufacturing process capable of supporting the customers' particular needs, ranging from small quantities for clinical trials to full commercial production, in all cases providing inexpensively produced, pure drugs. It has provided screening services to various innovator and generic pharmaceutical manufacturers. Enzyme Optimization Services The company works with its customers throughout the pharmaceutical product lifecycle to customize enzymes, resulting in optimized enzymes that have been evolved to perform a desired process according to a selective set of specifications. Its enzyme optimization services allow innovators to improve the manufacturing process as their drug candidates progress through preclinical and clinical development, in some cases deferring or reducing the need for significant manufacturing investment until the likelihood of commercial success is more certain; and enable manufacturing processes that require relatively little energy, reduce the need for hazardous reagents and reduce waste. Enzymes The company supplies varying quantities of its enzymes to pharmaceutical companies, from small to moderate quantities while they are optimizing their production processes, to larger quantities during later-stage clinical development and commercial scale drug production. The company’s enzymes enable innovators to manufacture products during preclinical and clinical development using optimized enzymatic processes, with relatively low investment; eliminate the need for innovators to invest in the development of complex chemical synthesis routes during the development stage; allow innovators to achieve higher product purity during the development stage prior to investing in expensive late-stage clinical trials; reduce the risk of adverse effects arising from product impurities; allow the removal of entire steps from synthetic chemical production routes during commercial scale production, reducing raw material costs, energy requirements and the need for capital expenditures; and decrease the manufacturing costs for its customers. The company has collaboration with Merck for the development of enzyme for use in a new manufacturing process for sitagliptin, the API in Merck's pharmaceutical product Januvia. Januvia is Merck's first-in-class medication for the treatment of Type II diabetes. Fine Chemicals Products and Services The company entered the fine chemicals market in 2013, specifically through application of biocatalysis technology in the commercial food space when it signed a joint development agreement with a food ingredients company. Additionally, its technology is also being used by a customer to manufacture butadiene, an intermediate for the manufacture of polymers. Intellectual Property As of December 31, 2013, the company owned or controlled approximately 394 issued patents and approximately 301 pending patent applications in the United States and in various foreign jurisdictions. Trademarks The company’s registered and pending United States and foreign trademarks include Codexis, Codex, CodeEvolver, CodeXporter, CodeXol, CodeXyme, Powered by CodeEvolver, We Are Biocatalysis, Mosaic, Sage, Microcyp, Hit from a Kit, Prosar and a Codexis and design mark (i.e., the Codexis logo). Competition The company competes with Novozymes, DSM, Cambrex Corporation and Almac Group Ltd. It also competes with BRAIN AG, C-LEcta GmbH and evocatal GmbH. The company’s competitors in the fine chemical markets include Dupont-Genencor, DSM, Novozymes and A.B. Enterprises. History Codexis, Inc. was founded in 2002. The company was incorporated in Delaware in 2002.
(CDXS:Consolidated Issue Listed on NASDAQ Global Select )
200 Penobscot Drive
Redwood City, CA 94063
|Cambrex Corp||$37.02 USD||+1.31|
|Koninklijke DSM NV||€49.20 EUR||-1.02|
|Novozymes A/S||kr306.40 DKK||-9.60|
|Takasago International Corp||¥542.00 JPY||-13.00|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact CODEXIS INC, please visit www.codexis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.